The first evidence that oncogenic MYC may suppress the antitumor immune response was the finding that MYC-expressing cancer cells downregulate major histocompatibility complex protein I (MHC I), which is critical for cytotoxic CD8+ T cells to recognize and specifically kill tumor cells [120,121,122,123]. This evidence concerns the gene CD8A and neoplasm.